Expert Review of Anti-infective Therapy最新文献_第2页

What is the role of immune responses to phage in phage therapy? 在噬菌体治疗中，免疫应答对噬菌体的作用是什么？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-14 DOI: 10.1080/14787210.2026.2659723

Krystyna Dąbrowska

引用次数: 0

New treatment strategies for mansonellosis: an expert overview. 曼氏菌病的新治疗策略：专家综述。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-05 DOI: 10.1080/14787210.2026.2653752

Uziel Ferreira Suwa, Enide Luciana Belmont Montefusco, Cláudia Patrícia Mendes de Araújo, Paulo Bonates, James Lee Crainey

{"title":"New treatment strategies for mansonellosis: an expert overview.","authors":"Uziel Ferreira Suwa, Enide Luciana Belmont Montefusco, Cláudia Patrícia Mendes de Araújo, Paulo Bonates, James Lee Crainey","doi":"10.1080/14787210.2026.2653752","DOIUrl":"10.1080/14787210.2026.2653752","url":null,"abstract":"Introduction: Mansonellosis, a filarial disease caused by Mansonella genus parasites, affects hundreds of millions globally and represents a growing public health challenge. Currently, there are no coordinated international mansonellosis management programs or guidelines, but there is a growing recognition that mansonellosis control interventions do need to be formulated.Areas covered: Between 1 January 2025 and 1 September 2025, the search-terms 'Mansonellosis' and 'Mansonella' were used to identify literature concerning macrofilaricidal and microfilaricidal chemotherapeutic treatment of mansonellosis in the PubMed and Web-of-Science databases. Identified literature revealed Mansonella ozzardi susceptibility and regional community-support levels make mass drug administration with ivermectin (MDAi) viable for mansonellosis control in the Americas. Macrofilaricidal test-and-treat programs were found to be more appealing for African mansonellosis control because of sub-optimal M. perstans and M. streptocerca microfilaricidal responses. Shortening treatment times could, however, make curative macrofilaricides the best option in Africa and the Americas.Expert opinion: The susceptibility of M. ozzardi to ivermectin and the growing appeal of MDAi for malaria control will present opportunities for synergistic malaria-mansonellosis control programs in the Americas. New short course curative macrofilaricides, which are in development for onchocerciasis and lymphatic filariasis, will likely be useful for mansonellosis treatment and will make the disease much easier to manage.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"325-336"},"PeriodicalIF":3.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Macrolides for community-acquired pneumonia: are there differences? 大环内酯类药物治疗社区获得性肺炎：有区别吗？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-14 DOI: 10.1080/14787210.2026.2656308

Marcial Cariqueo, Nicolas Severino, Antoni Torres

引用次数: 0

Cytomegalovirus antiviral stewardship considerations in solid organ transplant patients. 实体器官移植患者巨细胞病毒抗病毒管理的考虑。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2025-10-27 DOI: 10.1080/14787210.2025.2579205

Hanna L Kleiboeker, Margaret R Jorgenson

{"title":"Cytomegalovirus antiviral stewardship considerations in solid organ transplant patients.","authors":"Hanna L Kleiboeker, Margaret R Jorgenson","doi":"10.1080/14787210.2025.2579205","DOIUrl":"10.1080/14787210.2025.2579205","url":null,"abstract":"Introduction: There is a growing acknowledgment of the importance of stewardship initiatives in solid organ transplant given the increased potential for morbidity and mortality. Antiviral stewardship, particularly as it pertains to cytomegalovirus (CMV), has been most extensively studied.Areas covered: This review outlines the history and development of stewardship interventions in the solid organ transplant population with a focus on antiviral stewardship of CMV. Obstacles and proposed solutions to these obstacles from the vantage point of the UW Health experience are shared. Proposed future applications of the antiviral stewardship framework and structure are discussed. A systematic review of English language studies published since 2000 was performed. Search terms included solid organ transplant, antimicrobial stewardship, antiviral stewardship, post-transplant viral infections, and cytomegalovirus.Expert commentary: Antimicrobial stewardship has a role in the immunocompromised host, and CMV antiviral stewardship is a unique application in solid organ transplant. Utilization of this initiative can improve outcomes related to CMV, particularly in the high-risk population providing a proactive, dedicated effort with a well-established infrastructure for effective surveillance after prophylaxis. Targeted quality improvement initiatives can further personalize the initiative to address issues unique to each transplant center. Large scale or all-encompassing efforts are not required to obtain substantial benefit.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"315-323"},"PeriodicalIF":3.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in the clinical management of tuberculous meningitis. 结核性脑膜炎临床管理的最新进展。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2025-10-23 DOI: 10.1080/14787210.2025.2579210

Ravindra Kumar Garg

{"title":"Updates in the clinical management of tuberculous meningitis.","authors":"Ravindra Kumar Garg","doi":"10.1080/14787210.2025.2579210","DOIUrl":"10.1080/14787210.2025.2579210","url":null,"abstract":"Introduction: Tuberculous meningitis is frequently associated with significant mortality and persistent neurological sequelae. Diagnosis is often delayed due to nonspecific symptoms and the low sensitivity of cerebrospinal fluid (CSF) tests. Standard pulmonary tuberculosis regimens are suboptimal for central nervous system involvement due to poor drug penetration and prolonged treatment. Emerging resistance, particularly to rifampicin and isoniazid, further complicates the management.Areas covered: This review synthesizes recent data particularly on diagnostic tools, drug treatment, host-directed treatments, and supportive care in tuberculous meningitis. We summarize updated WHO recommendations and explore the pharmacokinetics and CSF penetration of antituberculosis drugs. Emphasis is placed on high-dose rifampicin, linezolid, and novel oxazolidinones such as sutezolid and delpazolid. Special populations, including children, pregnant women, those with human immunodeficiency virus, and drug-resistant disease are reviewed separately. The latest information of a variety of host-directed therapies is discussed. The utility of artificial intelligence for diagnosis and prognostication is also discussed.Expert commentary: Despite advances, tuberculous meningitis remains a clinical challenge. Early diagnosis, optimized dosing, and host-directed therapy are key priorities. Individualized regimens based on pharmacokinetics, drug resistance, and host factors are urgently needed. Precision diagnostics, new therapeutic agents, and artificial intelligence - driven tools may reduce mortality and improve outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"337-354"},"PeriodicalIF":3.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145344521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in therapeutic strategies against Mycobacterium marinum infection. 海洋分枝杆菌感染的治疗策略研究进展。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-01 DOI: 10.1080/14787210.2026.2652893

Wenhao Cheng, Chongyang Du, Shuangshuang Zhang, Guan Jiang, Wenlong Hu

{"title":"Advances in therapeutic strategies against Mycobacterium marinum infection.","authors":"Wenhao Cheng, Chongyang Du, Shuangshuang Zhang, Guan Jiang, Wenlong Hu","doi":"10.1080/14787210.2026.2652893","DOIUrl":"10.1080/14787210.2026.2652893","url":null,"abstract":"Introduction: There is currently no unified standard treatment for Mycobacterium marinum (M. marinum) infection, and its treatment faces clinical challenges, such as limited drug options and increasing drug resistance. Therefore, reviewing the progress in its treatment is of significant importance for guiding clinical practice. This article systematically reviews the advances in the treatment of M. marinum infection.Areas covered: This study systematically reviewed relevant literature by searching four electronic databases, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and Wan Fang database, for publications up to 1 January 2026, and summarized the current treatment landscape of M. marinum infections, including oral antibacterial monotherapy and combination regimens, novel local treatments such as photodynamic therapy, and adjuvant therapies including hyperthermia, surgical interventions, and immunomodulation.Expert opinion: M. marinum infection can involve the skin and deep tissues, and standardized diagnosis and treatment are pivotal for improving its prognosis. Optimizing antimicrobial regimens and applying novel local therapies hold considerable value, yet critical issues, such as the lack of treatment standards, persist. Future multicenter studies and precision treatment models are needed to establish a new paradigm of precise, diversified, and standardized clinical management.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"355-362"},"PeriodicalIF":3.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis? 酿酒酵母可以作为外阴阴道念珠菌病的治疗剂吗？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-03-01 Epub Date: 2026-04-19 DOI: 10.1080/14787210.2026.2659774

Mart Sillen, Silke Baldewijns, Paul Vandecruys, Patrick Van Dijck

{"title":"Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?","authors":"Mart Sillen, Silke Baldewijns, Paul Vandecruys, Patrick Van Dijck","doi":"10.1080/14787210.2026.2659774","DOIUrl":"10.1080/14787210.2026.2659774","url":null,"abstract":"Introduction: Vulvovaginal candidiasis (VVC) is a highly prevalent fungal vaginal infection with a substantial impact on women's quality of life. Increasing evidence indicates that VVC pathogenesis is driven not only by high fungal burden but also by dysregulated host-immune responses, highlighting the need for therapeutic strategies that extend beyond conventional antifungal treatment.Areas covered: In this review, recent advances elucidating the antifungal and immunomodulatory properties of Saccharomyces cerevisiae in the context of (recurrent) VVC are critically examined. Evidence from in vitro, ex vivo, in vivo, and clinical studies is integrated to assess S. cerevisiae-mediated attenuation of Candida virulence, modulation of host inflammatory responses, and interactions with the vaginal microbiota. In addition, translational challenges, safety considerations, regulatory constraints, and the therapeutic potential of yeast-based combination strategies are discussed.Expert opinion: S. cerevisiae treatment will play a role in both the prevention of recurrence/occurrence of Candida infections and the integration into combination regimens, where they can complement antifungal and host-directed therapies rather than function as standalone treatments. Future advances will depend on patient stratification, strain-specific optimization, and the integration of microbial therapies into combination treatment frameworks aimed at restoring and maintaining mucosal homeostasis.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"309-314"},"PeriodicalIF":3.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted screening for HTLV-1 infection in endemic and non-endemic regions: a global public health priority. 在流行和非流行地区有针对性地筛查HTLV-1感染：全球公共卫生重点。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-02-01 Epub Date: 2026-02-21 DOI: 10.1080/14787210.2026.2635426

Shigeo Fuji, Tatiane Assone, Jorge Casseb

{"title":"Targeted screening for HTLV-1 infection in endemic and non-endemic regions: a global public health priority.","authors":"Shigeo Fuji, Tatiane Assone, Jorge Casseb","doi":"10.1080/14787210.2026.2635426","DOIUrl":"10.1080/14787210.2026.2635426","url":null,"abstract":"Introduction: Human T-cell lymphotropic virus type 1 (HTLV-1) is an oncogenic retrovirus responsible for adult T-cell leukemia/lymphoma and chronic inflammatory diseases. Although at least several million individuals are infected worldwide, surveillance remains limited and the infection is frequently overlooked. Global migration has altered the epidemiology of HTLV-1, increasing the number of carriers in previously low-prevalence regions and creating hidden high-risk clusters. As universal population screening is not cost-effective, targeted testing of groups with elevated risk has become a critical public health priority.Areas covered: This review summarizes the changing global distribution of HTLV-1 and examines evidence supporting targeted screening strategies. A literature review was conducted focusing on epidemiological data, transmission dynamics, and policy initiatives in both endemic and non-endemic settings. Populations evaluated include migrants from endemic regions, family members of carriers, individuals with sexually transmitted infections, pregnant women, blood and organ donors, and patients with clinical conditions strongly associated with HTLV-1.Expert opinion: Expanding targeted screening offers a practical approach to reduce transmission and enable earlier clinical intervention. Integration of HTLV-1 testing into antenatal care, sexual health services, and specialty clinics is feasible. Broader recognition of HTLV-1 will be essential to reducing the global burden of this neglected infection.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"203-212"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis. 尼马特利韦/利托那韦对门诊患者长期COVID风险的影响：系统评价和荟萃分析

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-02-01 Epub Date: 2026-02-21 DOI: 10.1080/14787210.2026.2636175

Cucunawangsih Cucunawangsih, Arif Nur Muhammad Ansori, Akhil Deepak Vatvani, Timotius Ivan Hariyanto

{"title":"Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.","authors":"Cucunawangsih Cucunawangsih, Arif Nur Muhammad Ansori, Akhil Deepak Vatvani, Timotius Ivan Hariyanto","doi":"10.1080/14787210.2026.2636175","DOIUrl":"10.1080/14787210.2026.2636175","url":null,"abstract":"Background: This study systematically synthesized existing evidence to evaluate whether outpatient treatment with nirmatrelvir/ritonavir during the acute phase reduces the incidence of long COVID.Methods: We conducted a systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library from inception to 15 September 2025. Eligible studies compared COVID-19 outpatients prescribed nirmatrelvir/ritonavir during the acute phase with those who did not receive the drug. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.Results: Nineteen studies met inclusion criteria. Overall, nirmatrelvir/ritonavir use during acute infection was associated with a significant reduction in the likelihood of developing post-COVID-19 condition (OR 0.85; 95% CI: 0.80-0.91; p < 0.00001; I2 = 99%). Protective effects were consistently observed across multiple clinical domains, including cardiovascular (arrhythmia, ischemic disease, heart failure), pulmonary (dyspnea, COPD), thromboembolic (DVT, PE), neurological (stroke, cognitive impairment, headache), psychiatric (depression), gastrointestinal, metabolic (new-onset diabetes), renal (AKI), and general symptoms (malaise and fatigue). Conversely, no significant differences were noted for cough, asthma, dysautonomia, anxiety, PTSD, sleep disturbances, musculoskeletal pain, or olfactory/gustatory dysfunction.Conclusions: Early outpatient treatment with nirmatrelvir/ritonavir may mitigate the risk of developing several domains of long COVID, though its benefits are not uniform across all symptom categories.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"271-284"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of combination antibiotic therapy on mortality in patients with sepsis or septic shock due to Pseudomonas aeruginosa bloodstream infections: a systematic review. 联合抗生素治疗对铜绿假单胞菌血流感染脓毒症或脓毒性休克患者死亡率的影响：一项系统综述。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-02-01 Epub Date: 2026-02-25 DOI: 10.1080/14787210.2026.2635427

Caglayan Merve Ayaz, Ozlem Cakin, Selma Turan Kavradım, Mestan Emek, Melike Yüce Aktepe, Zeynep Özer

{"title":"The effect of combination antibiotic therapy on mortality in patients with sepsis or septic shock due to Pseudomonas aeruginosa bloodstream infections: a systematic review.","authors":"Caglayan Merve Ayaz, Ozlem Cakin, Selma Turan Kavradım, Mestan Emek, Melike Yüce Aktepe, Zeynep Özer","doi":"10.1080/14787210.2026.2635427","DOIUrl":"10.1080/14787210.2026.2635427","url":null,"abstract":"Introduction: Pseudomonas aeruginosa bloodstream infections (BSIs) complicated by sepsis or septic shock are associated with high mortality. Although combination antibiotic therapy may increase early antimicrobial coverage, its effect on survival remains uncertain. This systematic review evaluated the impact of appropriate empirical and definitive combination therapy compared with monotherapy on mortality in this population.Methods: Following PRISMA guidelines, we systematically searched eight databases through 31 August 2025, for studies enrolling adults with sepsis or septic shock due to confirmed P. aeruginosa BSIs that compared combination therapy with monotherapy. Data on study characteristics, treatment phase, and mortality outcomes were extracted. Risk of bias was assessed using ROBINS-I, and certainty of evidence was evaluated with GRADE.Results: Eight observational studies including 1201 patients met the inclusion criteria. No consistent survival benefit was observed with definitive combination therapy. Some studies assessing empirical therapy reported lower mortality in selected high-risk subgroups; however, results were characterized by substantial clinical heterogeneity. Adverse events were infrequently reported, and overall certainty of evidence was very low.Conclusions: Current evidence does not support routine use of combination therapy over monotherapy. Empirical combination therapy may be considered in carefully selected high-risk patients, with prompt de-escalation once susceptibilities are known.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"259-269"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0